Ankylosing Spondylitis Disease Activity Score (ASDAS) by anti-drug
Por um escritor misterioso
Descrição
PDF) The Value of the Ankylosing Spondylitis Disease Activity Score (Asdas) in Evaluating Disease Activity in Patients with Axial Spondyloarthritis
Full article: Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort - ACR Meeting Abstracts
Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?, Arthritis Research & Therapy
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Disease Control Data, Ankylosing Spondylitis
Table IV from Assessment of ankylosing spondylitis.
Axial Spondyloarthritis: Clinical Characteristics, Epidemiology, and General Approaches to Management - European Medical Journal
Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity
TNF Inhibitor Therapy, Ankylosing Spondylitis
SIMPONI ARIA® Ankylosing Spondylitis: Partial Remission
de
por adulto (o preço varia de acordo com o tamanho do grupo)
